Updates are available Correction dated 2024-11-14
Click to view Correction: https://doi.org/10.1038/s41587-024-02502-x
-
Authors
Oh, Sangwook https://orcid.org/0000-0003-0092-9031
Mao, Xuming https://orcid.org/0000-0003-4232-8103
Manfredo-Vieira, Silvio https://orcid.org/0000-0001-8036-4223
Lee, Jinmin
Patel, Darshil
Choi, Eun Jung
Alvarado, Andrea
Cottman-Thomas, Ebony
Maseda, Damian https://orcid.org/0000-0003-0722-6881
Tsao, Patricia Y. https://orcid.org/0000-0002-8800-1846
Ellebrecht, Christoph T.
Khella, Sami L.
Richman, David P.
O’Connor, Kevin C. https://orcid.org/0000-0002-7056-419X
Herzberg, Uri
Binder, Gwendolyn K.
Milone, Michael C.
Basu, Samik
Payne, Aimee S. https://orcid.org/0000-0001-9389-7918
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2019R1A6A3A03033057)
No Grant number funding for Cabaletta Bio
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01-AI114780, R21-AI142198, R01-AI114780, R21-AI142198)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 22 March 2022
Accepted: 8 December 2022
First Online: 19 January 2023
Change Date: 14 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-024-02502-x
Competing interests
: S.O. is involved with patent licensing from Cabaletta Bio. J.L., D.P., A.A., E.C.-T., U.H., G.K.B. and S.B. are employed by Cabaletta Bio. C.T.E. is involved with equity and patent licensing from Cabaletta Bio and patent licensing from Novartis. S.L.K. is a consultant for Catalyst, Alexion and Argenx. D.P.R. obtained a research grant from Cabaletta Bio. K.C.O. is involved with equity and obtained a research grant from Cabaletta Bio; is involved with research support, is a consultant and has received speaker fees from Alexion/AstraZeneca; has provided research support and received speaking fees from Viela Bio/Horizon Therapeutics; and is a consultant for and has received speaking fees from Roche and received speaking fees from Genentech and UCB. M.C.M. is involved with equity and has received payment, a research grant and patent licensing from Cabaletta Bio, as well patent licensing from Novartis and Tmunity, and is involved with equity and has received patent licensing from Verismo. A.S.P. is involved with equity, has received payment, research grant and patent licensing from Cabaletta Bio and patent licensing from Novartis, and is a consultant to Janssen. X.M., S.M.-V., E.J.C., D.M. and P.Y.T. declare no competing interests.
